SUNPHARMA Sun Pharmaceuticals Industries Ltd Product Launches Announcement 2024 - FDA Fast Track Approval Sun Pharmaceutical and Moebius Medical received FDA Fast Track designation for MM-II, a treatment for osteoarthritis knee pain, facilitating its development and review process. The drug showed significant efficacy in a Phase 2b study, providing pain relief for up to 26 weeks after a single injection..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Sun Pharmaceuticals Industries Ltd